Basic and clinical research of treatment for ocular disease by KANPO-drugs

1.基础研究我们观察了康宝口服液对实验性葡萄膜炎的影响。本文报道了从实验中获得的新证据：(1)在前列腺素E_2(10微克/毫升)治疗前，外用10倍人体临床剂量的康宝丸对实验性葡萄膜炎的治疗作用。(2)对脂多糖诱导的实验性葡萄膜炎的治疗作用。(1)在给予脂多糖(0.5mug/kg)治疗前，给予临床剂量5倍的KAKON-TO 1周。但不能抑制实验性葡萄膜炎的发生。(2)在给予脂多糖(0.5mug/kg)前，给予SAIREI-to 1周。在人临床剂量的10倍和3倍剂量下，与对照组相比，实验性葡萄膜炎明显受到抑制。

1. Basic researchWe investigated the effects of KANPO-druds for experimental uveitis. we report the results of new evidence acquired from the experiments.(1) The effects of KANPO-druds for experimental uveitis induced by topical prostaglandin E_2 KANPO-druds of ten-fold doses of human clinical dose were adiministered for 1 week before prostaglandin E_2 (10mug/ml) -treatment.The KANPO-druds of SAIREI-TO,KAKKON-TO and ORENGEDOKU-TO,respectively, did not inhibited the experimental uveitis.(2) The effects of KANPO-druds for experimental uveitis induced by lipopolysaccaharide(1) KAKKON-TO of five-fold doses of human clinical dose were administered for 1 week before lipopolysaccharide (0.5mug/kg) -treatment. But, the experimental uveitis were not inhibited.(2) SAIREI-TO were administered for 1 week before lipopolysaccharide (0.5mug/kg) -treatment. In ten-fold and three-fold doses of human clinical dose of SAIREI-TO,the experimental uveitis were significantly inhibited compared with control.